Chronic kidney disease and stroke

Advances in Chronic Kidney Disease

Volumn 21, Issue 6, 2014, Pages 500-508

  El Husseini, Nada ^a,b   Kaskar, Omran ^a,b   Goldstein, Larry B ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Neurology ^*  (United States)

Author keywords

Alteplase; Chronic kidney disease; Stroke; Stroke prevention; Thrombolysis

Indexed keywords

ANTITHROMBOCYTIC AGENT; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAROTID ARTERY SURGERY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIETITIAN; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HEMATOLOGIST; HUMAN; INFLAMMATION; NEPHROLOGIST; NEUROLOGIST; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACIST; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; THROMBOCYTE DYSFUNCTION; ADVERSE EFFECTS; COMPLICATION; INTRACRANIAL HEMORRHAGES; PATIENT CARE; RENAL INSUFFICIENCY, CHRONIC; SECONDARY PREVENTION; STROKE; THROMBOCYTE DISORDER;

ANTICOAGULANTS; BLOOD PLATELET DISORDERS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACRANIAL HEMORRHAGES; PATIENT CARE TEAM; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SECONDARY PREVENTION; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84927656384     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.09.001     Document Type: Review

References (79)

1. Centers for Disease Control and Prevention (CDC). National Chronic Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014. Accessed September 25, 2014. http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm#1.
2. Muntner P., Judd S.E., McClellan W., Meschia J.F., Warnock D.G., Howard V.J. Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Nephrol Dial Transplant 2012, 27(1):166-173.
3. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292.
4. Ninomiya T., Perkovic V., Verdon C., et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am J Kidney Dis 2009, 53(3):417-425.
5. Lee M., Saver J.L., Chang K.H., Liao H.W., Chang S.C., Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010, 341:c4249.
6. Abramson J.L., Jurkovitz C.T., Vaccarino V., Weintraub W.S., McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003, 64(2):610-615.
7. Ovbiagele B., Wing J.J., Menon R.S., et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke 2013, 44(9):2409-2413.
8. Bugnicourt J.M., Godefroy O., Chillon J.M., Choukroun G., Massy Z.A. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol 2013, 24(3):353-363.
9. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2013, US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
10. Go A.S., Fang M.C., Udaltsova N., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009, 119(10):1363-1369.
11. Wang H.H., Hung S.Y., Sung J.M., Hung K.Y., Wang J.D. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis 2014, 63(4):604-611.
12. Power A. Stroke in dialysis and chronic kidney disease. Blood Purif 2013, 36(3-4):179-183.
13. Murray A.M., Seliger S., Lakshminarayan K., Herzog C.A., Solid C.A. Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol 2013, 24(7):1166-1173.
14. Sozio S.M., Armstrong P.A., Coresh J., et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009, 54(3):468-477.
15. Lee J.G., Lee K.B., Jang I.M., et al. Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. Cerebrovasc Dis 2013, 35(1):53-59.
16. Bos M.J., Koudstaal P.J., Hofman A., Breteler M.M. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007, 38(12):3127-3132.
17. Molshatzki N., Orion D., Tsabari R., et al. Chronic kidney disease in patients with acute intracerebral hemorrhage: association with large hematoma volume and poor outcome. Cerebrovasc Dis 2011, 31(3):271-277.
18. Kumai Y., Kamouchi M., Hata J., et al. Proteinuria and clinical outcomes after ischemic stroke. Neurology 2012, 78(24):1909-1915.
19. Herzog C.A., Asinger R.W., Berger A.K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011, 80(6):572-586.
20. Yahalom G., Schwartz R., Schwammenthal Y., et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009, 40(4):1296-1303.
21. Casserly L.F., Dember L.M. Thrombosis in end-stage renal disease. Semin Dial 2003, 16(3):245-256.
22. Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004, 30(5):579-589.
23. Sharma S., Farrington K., Kozarski R., et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur HeartJ 2013, 34(5):354-363.
24. Rattanasompattikul M., Molnar M.Z., Zaritsky J.J., et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant 2013, 28(7):1936-1945.
25. Goldstein L.B., Bushnell C.D., Adams R.J., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42(2):517-584.
26. Shakeri A., Abdi M., Khosroshahi H.T., Fouladi R.F. Common carotid artery intima-media thickness and atherosclerotic plaques in carotid bulb in patients with chronic kidney disease on hemodialysis: a case-control study. Pak J Biol Sci 2011, 14(17):844-848.
27. van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?. Nephrol Dial Transplant 2006, 21(5):1161-1166.
28. Kwon H.M., Lee Y.S., Bae H.J., Kang D.W. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke 2014, 45(3):871-873.
29. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298(10):1163-1170.
30. Reinecke H., Engelbertz C., Schabitz W.R. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke 2013, 44(10):2935-2941.
31. Horio T., Iwashima Y., Kamide K., et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010, 28(8):1738-1744.
32. Alonso A., Lopez F.L., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011, 123(25):2946-2953.
33. Nelson S.E., Shroff G.R., Li S., Herzog C.A. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J Am Heart Assoc 2012, 1(4):e002097.
34. Winkelmayer W.C., Turakhia M.P. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission?. JAMA 2014, 311(9):913-915.
35. Soliman E.Z., Prineas R.J., Go A.S., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010, 159(6):1102-1107.
36. Carrero J.J., Evans M., Szummer K., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014, 311(9):919-928.
37. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial fibrillation) study cohorts. Circulation 2013, 127(2):224-232.
38. Nakagawa K., Hirai T., Takashima S., et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol 2011, 107(6):912-916.
39. Hart R.G., Eikelboom J.W., Brimble K.S., McMurtry M.S., Ingram A.J. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013, 29(suppl 7):S71-S78.
40. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012, 367(7):625-635.
41. Szeto C.C., Lai K.B., Kwan B.C., et al. Bacteria-derived DNA fragment in peritoneal dialysis effluent as a predictor of relapsing peritonitis. Clin J Am Soc Nephrol 2013, 8(11):1935-1941.
42. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138(5):1093-1100.
43. Holzmann M.J., Aastveit A., Hammar N., Jungner I., Walldius G., Holme I. Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population. Ann Med 2012, 44(6):607-615.
44. Menon B.K., Saver J.L., Prabhakaran S., et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012, 43(9):2293-2299.
45. Agrawal V., Rai B., Fellows J., McCullough P.A. In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke. Nephrol Dial Transplant 2010, 25(4):1150-1157.
46. Lyrer P.A., Fluri F., Gisler D., Papa S., Hatz F., Engelter S.T. Renal function and outcome among stroke patients treated with IV thrombolysis. Neurology 2008, 71(19):1548-1550.
47. Naganuma M., Koga M., Shiokawa Y., et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis 2011, 31(2):123-129.
48. Whiteley W.N., Slot K.B., Fernandes P., Sandercock P., Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012, 43(11):2904-2909.
49. Gensicke H., Zinkstok S.M., Roos Y.B., et al. IV thrombolysis and renal function. Neurology 2013, 81(20):1780-1788.
50. Kruger T., Brandenburg V., Schlieper G., Marx N., Floege J. Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant 2013, 28(3):534-541.
51. Wizemann V., Tong L., Satayathum S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010, 77(12):1098-1106.
52. Chan K.E., Lazarus J.M., Thadhani R., Hakim R.M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009, 20(10):2223-2233.
53. Winkelmayer W.C., Liu J., Setoguchi S., Choudhry N.K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011, 6(11):2662-2668.
54. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011, 6(11):2599-2604.
55. Shah M., Avgil Tsadok M., Jackevicius C.A., et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014, 129(11):1196-1203.
56. Lai H.M., Aronow W.S., Kalen P., et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2009, 2:33-37.
57. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society [epub ahead of print]. Circulation. Accessed September 30, 2014. http://dx.doi.org/10.1016/j.jacc.2014.03.021.
58. Yang F., Chou D., Schweitzer P., Hanon S. Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace 2010, 12(12):1666-1672.
59. Culebras A., Messe S.R., Chaturvedi S., Kase C.S., Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014, 82(8):716-724.
60. Kleinow M.E., Garwood C.L., Clemente J.L., Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011, 17(7):523-530.
61. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
62. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
63. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
64. Wagner J., Jhaveri K.D., Rosen L., Sunday S., Mathew A.T., Fishbane S. Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant 2014, 29(1):146-151.
65. Eikelboom J.W., O'Donnell M., Yusuf S., et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010, 159(3):348-353.e1.
66. Eikelboom J.W., Connolly S.J., Gao P., et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012, 21(6):429-435.
67. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012, 33(22):2821-2830.
68. Palmer S.C., Di Micco L., Razavian M., et al. Antiplatelet agents forchronic kidney disease. Cochrane Database Syst Rev 2013, 2:CD008834.
69. Floege J., Schlieper G. Chronic kidney disease: how effective and safe are antiplatelet agents in CKD?. Nat Rev Nephrol 2013, 9(6):314-316.
70. AbuRahma A.F., Srivastava M., Chong B., Dean L.S., Stone P.A., Koszewski A. Impact of chronic renal insufficiency using serum creatinine vs glomerular filtration rate on perioperative clinical outcomes of carotid endarterectomy. J Am Coll Surgeons 2013, 216(4):525-532. discussion 532-533.
71. Adil M, Saeed F, Qureshi A. Carotid Artery Stent Placement and Carotid Endarterectomy in Patients with Dialysis Dependent Renal Failure. Neurology. 2014;82(suppl 10):P7. 167-P7.
72. Nikolic D., Banach M., Nikfar S., et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Isthe duration of therapy important?. Int J Cardiol 2013, 168(6):5437-5447.
73. Strippoli G.F., Navaneethan S.D., Johnson D.W., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336(7645):645-651.
74. Erickson K.F., Japa S., Owens D.K., Chertow G.M., Garber A.M., Goldhaber-Fiebert J.D. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol 2013, 61(12):1250-1258.
75. Ridker P.M., MacFadyen J., Cressman M., Glynn R.J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010, 55(12):1266-1273.
76. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138(2):98-104.
77. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
78. Barylski M., Nikfar S., Mikhailidis D.P., et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013, 72:35-44.
79. Palmer S.C., Navaneethan S.D., Craig J.C., et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2013, (9):CD004289.